Dr. Maggie Fader (at Nicklaus Children's Hospital) discusses the ongoing Functional Precision Medicine Clinical Trial for relapsed or refractory pediatric cancer patients (NCTNCT05857969). This webinar will outline this team's unique approach to personalized medicine, utilizing patient specific ex vivo Drug sensitivity Testing (DST) and genomic profiling.
Dr. Maggie Fader: Functional Precision Medicine Clinical Trial
Previous
Previous
Dr. David Loeb: A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Next
Next